Senores Pharmaceuticals logo

Senores Pharmaceuticals financials: balance sheet, profit and loss, cash flow

NSE: SENORESBSE: 544319Pharmaceuticals & BiotechnologySmall Cap

Senores Pharmaceuticals Limited · Face value ₹10 · Listed Dec 2024 · Issue price ₹391
Last close ₹1,133.90down ₹85.30 (7.00%)BSE ₹1,133.60

Share price at the NSE close on 30 Oct 2026. Previous close ₹1,219.20.

30 Oct: open ₹1,219.20, high ₹1,228.00, low ₹1,053.40

52-week range of traded prices to 30 Oct 2026
₹706.00Low, 23 Mar 2026₹1,599.00High, 24 Aug 2026
Market cap
₹5,222 Cr841st largest listed
P/E
37.69
P/B
5.21
Dividend yield
Nonein the last 12 months
ROE
15.2%
ROCE
12.3%
Debt to equity
0.38
Volume, NSE
23,16,99133.7% delivered

Senores Pharmaceuticals' financial statements for the 2 years to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them.

2 years at a glance

₹ crore, years to March.Senores Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
39858305Mar 25633122327Mar 26

Operating and net margin, per cent

  • Operating margin
  • Net margin
26.6%14.6%22.5%26.6%14.6%19.2%Mar 25Mar 26

The years either side of a change of basis do not compare. From the year to Mar 2026, the company's revenue for that year, ₹633 Cr, differs from its quarters added, ₹650 Cr.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue633
  2. Materials and goods−252
  3. Employee costs−112
  4. Other expenses−100
  5. Operating profit168
  6. Depreciation−31
  7. Other income+47
  8. One-off items0.0
  9. Finance costs−25
  10. Profit before tax159
  11. Tax−38
  12. Net profit122

What the company owns

  • Plant, investments and other assets₹1,030 Cr
  • Receivables₹325 Cr
  • Cash and bank₹160 Cr
  • Inventory₹89 Cr

What pays for it: net worth and liabilities

  • Net worth₹965 Cr
  • Borrowings₹327 Cr
  • Owed to suppliers₹235 Cr
  • Other liabilities₹77 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Senores Pharmaceuticals quarterly results

₹ croreMar 2025Mar 2026Sep 2026Twelve monthsFiled 29 Oct
Revenue from operations398633722
309464509
Materials and goods bought181252266
Employee costs60112123
Other expenses67100121
Operating profit before depreciation90168213
Operating margin22.5%26.6%29.5%
Materials, % of revenue45.4%39.8%36.8%
Employee costs, % of revenue15.2%17.7%17.1%
Other expenses, % of revenue16.9%15.9%16.7%
Depreciation and amortisation173137
Operating profit after depreciation73137176
Other income194733
Finance costs222530
One-off items000
Profit before tax71159179
123842
58122137
Other comprehensive income−42941
Total comprehensive income55151178
Net margin14.6%19.2%19.0%
Belonging to the company's shareholders is left blank for the year to Mar 2025: the filing's earnings per share does not match the profit it states, and cannot be multiplied back into the owners' profit because the company's periods around it state no share for other owners for the gap to belong to.

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2025Mar 2026Sep 2026Half yearFiled 29 Oct
8129651,032
7869341,003
Share capital464646
Reserves740888957
Belonging to outside owners of subsidiaries263129
305327394
241424412
174215237
Total assets1,2271,6041,681
504791914
722812766
Net debt−81167294
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2025Mar 2026Sep 2026Half year
−466229
−507535
−134−142−85
Receivables−12−19772
Inventories−19−30−8
Payables−46161−84
Other working capital−58−75−64
Tax paid−9−13−9
Interest paid2000
Capital spending158240137
Free cash flow−203−178−107
−429−121−112
573−155
Dividends paid000
Shares bought back000
Shares issued47200
Net change in cash98−60−28
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2025Mar 2026
Earnings per share₹16.12₹26.39
Diluted earnings per share₹16.12₹26.39
Book value per share₹170.71₹202.74
Shareholder yield−18.0%0.0%
Market cap at the year end (₹ crore)2,6283,498

Ratios

Consolidated, years to March.Senores Pharmaceuticals PE ratio and valuation

RatioMar 2025Mar 2026
Net profit growth–108.3%
Earnings per share growth–63.7%
Return on equity–14.1%
Return on capital employed6.5%10.6%
Cash conversion−78.7%51.1%
Interest cover3.45.5
Debt to equity0.380.34
Receivable days114187
Inventory days114130
Payable days136340
Cash conversion cycle, days92−24
Working capital days219208
Asset turnover0.320.45
Assets per rupee of net worth1.561.65
Sales per rupee of plant2.001.91
Capital spending to depreciation9.357.68
Plant being built, % of plant in use22.2%5.3%
Revenue growth and operating profit growth are left blank for the year to Mar 2026: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
8.6%
Cash from operations against operating profit
36.9%
Measure3 years
Return on capital employed, average8.6%
Operating margin, average24.6%
Net margin, average16.9%
Asset turnover, average0.39
Cash conversion cycle, days, average34
Interest cover, average4.4
Debt to equity, average0.36

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations62
Cash from investing−121
Cash from financing−1
Capital spending240
Dividends paid0
Shares bought back0
Shares issued for cash0
Borrowings raised13
Borrowings repaid16

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2025Mar 2026
Altman Z-scorePublished threshold 1.815.695.12
Beneish M-scorePublished threshold −1.78–−1.21
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–12.72
Receivables growth less revenue growthOur threshold 0 percentage points–103.35
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–18.40
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–13.01
Assets under construction, years of additionsOur threshold 2 years of additions–0.11
Effective tax ratePublished threshold 17.16 per cent17.3323.61
Tax charged less tax paid, % of profitOur threshold 10 percentage points4.3415.32
A threshold marked as ours has no published figure; it is the line we read the check against.